Radionuclide labeled microspheres have gained acceptance in the localized treatment of a number of cancer types. Historically, the most widely known version of this therapy modality has been hepatic artery delivered yttrium-90 (Y-90) microspheres used in the treatment of liver primary and metastatic tumors. New research has resulted in more localized treatment with liver-directed Y-90 microspheres, as well as, expanded both the radionuclides used and the organ sites within which tumors can be treated. The content presented in this session will span from current state of the art with liver directed Y-90 microspheres, to research into site specific brain and pancreatic tumor treatments, and the utilization of the radionuclides Holmium-166 and Phosphorus-32.
1. Understanding of microsphere dosimetry.
2. Familiarity with requirements and limitations regarding the accuracy of emission-imaging based microspheres dosimetry.
3. Familiarity with new techniques required for organ site specific microsphere delivery.
4. Introduction to the decision-making process regarding the choice of a radionuclide for radiolabeled microspheres therapy.